Aeterna Zentaris
Aeterna Zentaris, Inc.
315 Sigma Drive
Summerville, SC 29486
Phone: (843) 900-3223Website: https://www.zentaris.com/
Latest news
- Aeterna Zentaris Announces FDA Approval of Macrilen (macimorelin) for Diagnosis of Adult Growth Hormone Deficiency
20 December 2017 - NDA for Macrilen for the Evaluation of Growth Hormone Deficiency in Adults Granted December 30, 2017 PDUFA Date
18 July 2017 - Aeterna Zentaris Resubmits NDA for Macrilen for the Evaluation of Growth Hormone Deficiency in Adults
30 June 2017 - Aeterna Zentaris Intends to File NDA with Respect to Macrilen in Third Quarter of 2017
30 March 2017 - Aeterna Zentaris Announces Plans to Pursue FDA Registration of Macrilen
13 February 2017 - Aeterna Zentaris Completes Patient Recruitment for Confirmatory Phase 3 Trial of Macrilen
26 October 2016 - Aeterna Zentaris Announces Plans to Initiate Phase 3 Study of Macrilen in AGHD
13 April 2015 - FDA Issues Complete Response Letter for Macrilen (macimorelin) NDA in Adult Growth Hormone Deficiency
6 November 2014 - Aeterna Zentaris NDA for Macimorelin Acetate in AGHD Accepted for Filing by the FDA
6 January 2014 - Aeterna Zentaris Submits New Drug Application to FDA for Macimorelin Acetate (AEZS-130) for Evaluation of AGHD
5 November 2013
Drugs Associated with Aeterna Zentaris, Inc.
Aeterna Zentaris, Inc. manufactures, markets and/or distributes 1 drug in the United States. Medications listed here may also be marketed under different names in different countries. Non-US country and region specific information is not available on this page.
| Brand/Generic Name | Reviews | Rating |
|---|---|---|
|
Macrilen
Generic name: macimorelin Drug class: growth hormones |
||
| For ratings, users were asked how effective they found the medicine while considering positive/adverse effects and ease of use (1 = not effective, 10 = most effective). | ||